← Search & browse all drugs

flutemetamol (18F)

V09AX04

Forms & Strengths

Single‑use sterile vial
Fluorine‑18 labeled flutemetamol
Activity 185–370 MBq (5–10 mCi) per dose
Prepared in saline for IV injection

Adult Dosing

IV bolus injection of 185–370 MBq (5–10 mCi) over ≤5 seconds
Inject 10 minutes before PET acquisition; imaging starts 90 minutes post‑injection
Adjust activity for patient weight >90 kg (up to 555 MBq)

Pediatric Dosing

Not approved for use in patients <18 years
Safety and dosing not established in pediatric population

Indications

Detection of cerebral amyloid plaques to aid diagnosis of Alzheimer’s disease
Differentiation of Alzheimer’s disease from other dementias
Research use in clinical trials of anti‑amyloid therapies

Mechanism of Action

Fluorine‑18 labeled analogue of thioflavin that binds with high affinity to β‑amyloid aggregates
After IV administration, crosses blood‑brain barrier and localizes to amyloid plaques
PET detects emitted positrons, providing a map of plaque distribution

Contraindications

Known hypersensitivity to flutemetamol or any excipients
Pregnancy (radiation exposure to fetus)
Breast‑feeding (radiation to infant)

Adverse Reactions

Mild headache
Nausea or vomiting
Transient injection‑site pain or erythema
Dizziness or feeling of warmth
Rare allergic reaction (urticaria, bronchospasm)

Drug Interactions

No clinically significant drug‑drug interactions reported
Concurrent administration of other PET radiopharmaceuticals may require spacing to avoid cross‑contamination
Avoid high‑dose iodinated contrast within 24 h if brain PET is planned (minimal effect)

Curated Content: Needs Vetting Before Put to Clinical Use